GOSS
Gossamer Bio, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-33/100
Last price
10.88
▲ 0.23 (2.19%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
10.72
Prev close
10.65
Day high
10.93
Day low
10.50
Volume
197.17K
Market cap
$65.93M
P/E (TTM)
—
52W range
9.12 – 309.60
Day trading desk
Gap from prior close
+0.66%
Prior close 10.65
VWAP
10.68
+1.93% from price
Relative volume
0.50×
Quiet session
Session range
15.00%
10.00 – 11.50
Position in range
59%
Mid range
ATR (14D)
1.17
10.78% of price
Prior day high
10.99
PDH
Prior day low
10.00
PDL
Bid / ask spread
—
Quote not published
Session volume
187.86K
Avg 375.81K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-6.91%
-8.9%
1M
-23.00%
-24.2%
3M
-20.27%
-24.8%
6M
-59.17%
-77.4%
YTD
-95.65%
-109.9%
1Y
-94.76%
-111.2%
3Y
-83.82%
-166.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GOSS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+27.60M
Net buying
Buy transactions
63
28.27M shares
Sell transactions
34
668.82K shares
Net transactions
+97
Buys less sells
Sell : buy shares
0.0 : 1
Mixed
Insider-held shares
87.63K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jan 2, 26 | HASNAIN FAHEEM Chief Executive Officer |
STOCK | 280.00K | $0 | Direct |
| Jan 2, 26 | GIRAUDO BRYAN M. Chief Operating Officer |
STOCK | 115.75K | $0 | Direct |
| Jan 2, 26 | PETERSON CARYN Officer |
STOCK | 84.50K | $0 | Direct |
| Jan 2, 26 | ARANDA RICHARD Officer |
STOCK | 93.75K | $0 | Direct |
| Jan 2, 26 | CHRISTIAN WAAGE Officer |
STOCK | 84.50K | $0 | Direct |
| Jan 2, 26 | SMITH ROBERT PAUL JR Officer |
STOCK | 93.75K | $0 | Direct |
| Oct 1, 25 | HASNAIN FAHEEM Chief Executive Officer |
STOCK | 437.50K | $0 | Direct |
| Oct 1, 25 | GIRAUDO BRYAN M. Chief Operating Officer |
STOCK | 181.25K | $0 | Direct |
| Oct 1, 25 | PETERSON CARYN Officer |
STOCK | 125.00K | $0 | Direct |
| Oct 1, 25 | ARANDA RICHARD Officer |
STOCK | 162.50K | $0 | Direct |
| Oct 1, 25 | CHRISTIAN WAAGE Officer |
STOCK | 125.00K | $0 | Direct |
| Oct 1, 25 | SMITH ROBERT PAUL JR Officer |
STOCK | 162.50K | $0 | Direct |
| Aug 19, 25 | MILLIGAN SANDRA Director |
BUY | 26.05K | $50.02K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ARANDA RICHARD |
Officer | 465.64K | Stock Award(Grant) |
CHRISTIAN WAAGE |
Officer | 882.17K | Stock Award(Grant) |
GIRAUDO BRYAN M. |
Chief Operating Officer | 869.75K | Stock Award(Grant) |
HASNAIN FAHEEM |
Chief Executive Officer | 6.25M | Stock Award(Grant) |
MILLIGAN SANDRA |
Director | 58.05K | Purchase |
PETERSON CARYN |
Officer | 259.33K | Stock Award(Grant) |
SMITH ROBERT PAUL JR |
Officer | 285.90K | Stock Award(Grant) |
Fundamentals
Market cap$65.93M
Enterprise value$48.91M
Revenue (TTM)$53.29M
Gross profit$53.29M
EBITDA$-158.60M
Net income$-125.22M
EPS (TTM)$-52.80
Free cash flow$-29.76M
Total cash$57.03M
Total debt$40.07M
Book value / share$-15.39
Shares outstanding6.12M
Float3.88M
Short % of float15.73%
Dividend yield0.00%
Beta (5Y)2.21
Valuation & profitability ratios
Trailing P/E—
Forward P/E-0.69
PEG ratio—
Price / sales—
Price / book—
EV / revenue0.92
EV / EBITDA-0.31
Gross margin100.00%
Operating margin-282.25%
Profit margin-235.00%
Return on equity—
Return on assets-62.39%
Debt / equity—
Current ratio0.53
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $48.47M | $114.70M | $0 | $0 | -57.7% |
| Operating revenue | $48.47M | $114.70M | $0 | $0 | -57.7% |
| Research & development | $174.09M | $138.49M | $135.30M | $170.92M | +25.7% |
| Selling, general & admin | $37.63M | $36.13M | $38.45M | $47.61M | +4.1% |
| Total operating expense | $211.72M | $174.62M | $173.76M | $218.53M | +21.2% |
| Operating income | -$163.25M | -$59.92M | -$173.76M | -$218.53M | -172.5% |
| Net interest income | -$9.02M | -$9.74M | -$11.51M | -$12.30M | +7.4% |
| Pre-tax income | -$170.46M | -$55.63M | -$179.82M | -$229.38M | -206.4% |
| Tax provision | -$88.00K | $893.00K | $0 | $0 | -109.9% |
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M | -201.4% |
| Net income to common | -$170.37M | -$56.53M | -$179.82M | -$229.38M | -201.4% |
| Basic EPS | -60.00 | -20.00 | -94.40 | -216.80 | -200.0% |
| Diluted EPS | -60.00 | -20.00 | -94.40 | -216.80 | -200.0% |
| EBIT | -$159.47M | -$44.12M | -$166.31M | -$215.50M | -261.5% |
| EBITDA | -$158.47M | -$39.97M | -$161.92M | -$211.07M | -296.5% |
| Basic shares | 2.86M | 2.83M | 1.91M | 1.06M | +1.0% |
| Diluted shares | 2.86M | 2.83M | 1.91M | 1.06M | +1.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $37.73M | $46.07M | $32.11M | $111.97M | -18.1% |
| Cash & short-term investments | $136.93M | $294.52M | $296.43M | $255.68M | -53.5% |
| Total current assets | $167.64M | $309.89M | $306.52M | $261.88M | -45.9% |
| Property, plant & equipment | $4.20M | $5.12M | $4.78M | $9.89M | -18.0% |
| Total assets | $172.25M | $315.29M | $311.92M | $272.45M | -45.4% |
| Total current liabilities | $63.44M | $45.01M | $51.60M | $49.23M | +40.9% |
| Current debt | — | — | $11.61M | $11.61M | — |
| Long-term debt | $198.51M | $197.52M | $197.41M | $207.70M | +0.5% |
| Total debt | $202.91M | $202.88M | $212.46M | $225.74M | +0.0% |
| Total liabilities | $295.01M | $285.80M | $249.15M | $260.37M | +3.2% |
| Retained earnings | -$1.44B | -$1.27B | -$1.21B | -$1.03B | -13.4% |
| Shareholder equity | -$122.76M | $29.49M | $62.77M | $12.08M | -516.2% |
| Working capital | $104.21M | $264.88M | $254.92M | $212.65M | -60.7% |
| Net tangible assets | -$122.76M | $29.49M | $62.77M | $12.08M | -516.2% |
| Shares issued | 2.92M | 2.83M | 2.82M | 1.18M | +3.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$170.37M | -$56.53M | -$179.82M | -$229.38M | — | -201.4% |
| Depreciation & amortisation | $1.00M | $4.15M | $4.38M | $4.43M | — | -75.9% |
| Stock-based compensation | $10.55M | $20.62M | $28.52M | $42.55M | — | -48.8% |
| Change in working capital | -$13.63M | $39.46M | -$14.84M | -$4.46M | — | -134.5% |
| Operating cash flow | -$171.27M | -$3.47M | -$159.16M | -$187.03M | — | -4,838.5% |
| Capital expenditure | -$79.00K | — | — | -$475.00K | -$1.62M | — |
| Investing cash flow | $156.36M | $29.02M | -$110.97M | -$1.03M | — | +438.7% |
| Financing cash flow | $6.42M | -$11.49M | $190.15M | $117.09M | — | +155.9% |
| Free cash flow | -$171.34M | -$3.47M | -$159.16M | -$187.51M | — | -4,840.7% |
| End cash position | $37.73M | $46.07M | $32.11M | $111.97M | — | -18.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $9.24M | $16.95M | $13.80M | $13.29M | $11.49M | -45.5% |
| Operating revenue | $9.24M | $16.95M | $13.80M | $13.29M | $11.49M | -45.5% |
| Research & development | $26.41M | $43.08M | $48.94M | $45.54M | $41.58M | -38.7% |
| Selling, general & admin | $8.90M | $18.75M | $10.90M | $9.39M | $8.68M | -52.5% |
| Total operating expense | $35.31M | $61.82M | $59.84M | $54.93M | $50.25M | -42.9% |
| Operating income | -$26.07M | -$44.87M | -$46.04M | -$41.64M | -$38.77M | +41.9% |
| Net interest income | -$2.44M | -$2.40M | -$2.30M | -$2.06M | -$2.20M | -1.5% |
| Pre-tax income | $16.90M | -$46.66M | -$47.33M | -$48.22M | -$38.27M | +136.2% |
| Tax provision | — | — | -$88.00K | $0 | $0 | — |
| Net income | $16.90M | -$46.66M | -$47.24M | -$48.22M | -$38.27M | +136.2% |
| Net income to common | $16.90M | -$46.66M | -$47.24M | -$48.22M | -$38.27M | +136.2% |
| Basic EPS | 4.00 | -16.00 | -16.80 | -16.80 | -13.60 | +125.0% |
| Diluted EPS | -6.40 | -16.00 | -16.80 | -16.80 | -13.60 | +60.0% |
| EBIT | $19.61M | -$43.91M | -$44.58M | -$45.47M | -$35.53M | +144.6% |
| EBITDA | $19.86M | -$43.68M | -$44.35M | -$45.25M | -$35.32M | +145.5% |
| Basic shares | 4.00M | 2.93M | 2.83M | 2.85M | 2.84M | +36.7% |
| Diluted shares | 4.11M | 2.93M | 2.83M | 2.85M | 2.84M | +40.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.15M | $41.03M | $37.73M | $8.93M | $26.31M | — | +0.3% |
| Cash & short-term investments | $57.03M | $99.22M | $136.93M | $180.22M | $212.92M | — | -42.5% |
| Total current assets | $72.72M | $124.54M | $167.64M | $203.99M | $235.90M | — | -41.6% |
| Property, plant & equipment | $3.71M | $3.96M | $4.20M | $4.42M | $4.64M | — | -6.4% |
| Total assets | $76.87M | $128.90M | $172.25M | $208.82M | $240.93M | — | -40.4% |
| Total current liabilities | $137.78M | $56.51M | $63.44M | $62.12M | $53.59M | — | +143.8% |
| Current debt | $36.15M | — | — | — | — | — | — |
| Long-term debt | — | $198.76M | $198.51M | $198.26M | $198.01M | $197.76M | — |
| Total debt | $40.07M | $202.93M | $202.91M | $202.88M | $202.83M | — | -80.3% |
| Total liabilities | $170.90M | $290.38M | $295.01M | $291.15M | $287.03M | — | -41.1% |
| Retained earnings | -$1.47B | -$1.49B | -$1.44B | -$1.39B | -$1.34B | — | +1.1% |
| Shareholder equity | -$94.03M | -$161.48M | -$122.76M | -$82.33M | -$46.11M | — | +41.8% |
| Working capital | -$65.06M | $68.03M | $104.21M | $141.87M | $182.30M | — | -195.6% |
| Net tangible assets | -$94.03M | -$161.48M | -$122.76M | -$82.33M | -$46.11M | — | +41.8% |
| Shares issued | 6.11M | 2.93M | 2.92M | 2.89M | 2.84M | — | +108.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $16.90M | -$46.66M | -$47.24M | -$48.22M | -$38.27M | — | +136.2% |
| Depreciation & amortisation | $252.00K | $232.00K | $227.00K | $220.00K | $213.00K | — | +8.6% |
| Stock-based compensation | $2.46M | $6.30M | $2.90M | $2.67M | $2.59M | — | -60.9% |
| Change in working capital | -$14.04M | $1.81M | -$3.36M | $3.03M | -$9.89M | — | -874.9% |
| Operating cash flow | -$39.42M | -$38.72M | -$48.31M | -$36.17M | -$47.06M | — | -1.8% |
| Capital expenditure | — | — | — | — | -$53.00K | -$26.00K | — |
| Investing cash flow | $42.70M | $41.61M | $73.16M | $17.01M | $44.13M | — | +2.6% |
| Financing cash flow | -$3.14M | $512.00K | $3.96M | $1.87M | $94.00K | — | -714.1% |
| Free cash flow | -$39.42M | -$38.72M | -$48.31M | -$36.17M | -$47.11M | — | -1.8% |
| End cash position | $41.15M | $41.03M | $37.73M | $8.93M | $26.31M | — | +0.3% |
Options analytics
Put / call volume
1.00
Call-heavy session
Put / call open interest
0.10
Positioning, not flow
Max pain
0.50
-95.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
+50.0%
Puts bid over calls
Call volume
5
Contracts, this expiry
Put volume
5
Contracts, this expiry
Heaviest call OI
0.50
177 contracts
Heaviest put OI
0.50
7 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -9.99 | -8.17 | +18.2% |
| Mar 2026 | -13.64 | -16.00 | -17.3% |
| Dec 2025 | -15.65 | -16.80 | -7.3% |
| Sep 2025 | -15.77 | -16.80 | -6.5% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -3.93 | 5 | $10.67M | -19.7% |
| Next quarter | -4.93 | 5 | $0 | -100.0% |
| Current year | -18.01 | 4 | $35.86M | -26.0% |
| Next year | -15.61 | 5 | $16.75M | -53.3% |
Analyst targets & ownership
Mean target$82.48
High target$120.00
Low target$22.40
Implied upside657.89%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 2
Hold3
Sell / Strong sell0 / 1
Held by insiders1.43%
Held by institutions84.88%
Institutions holding191
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
11.09
-1.85% from price
SMA 20
11.17
-3.51% from price
SMA 50
12.79
-15.69% from price
SMA 100
13.67
-20.40% from price
SMA 200
61.65
-82.51% from price
EMA 12
11.15
-2.39% from price
EMA 26
11.68
-6.82% from price
EMA 50
12.94
-15.90% from price
RSI (14)
42.6
Neutral
MACD (12,26,9)
-0.53
Hist 0.02
ATR (14)
1.17
10.88% of price
Realised vol 30D
102.4%
Annualised
Bollinger upper
12.31
20, 2σ
Bollinger lower
10.04
20, 2σ
50 / 200 cross
Death
12.79 vs 61.65
Trend bias
Below 200
-82.51%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.24
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
102.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-96.6%
Peak to trough
Max drawdown 5Y
-99.1%
Peak to trough
ATR 14
1.17
10.88% of price
Beta (reported)
2.21
5Y monthly, from filing
Short interest
Shares short
948.62K
Prior 1.08M
Change vs prior
-12.6%
Shorts covering
% of float
15.73%
Elevated
% of shares out
15.51%
Against total outstanding
Days to cover
3.3
Liquid
Float
3.88M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 14, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Jul 28, 26 | Leerink Partners | UPGRADE | Market Perform | Outperform |
| Jul 27, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jun 25, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 26, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 19, 26 | Barclays | MAINTAINED | Underweight | Underweight |
| Mar 23, 26 | Cantor Fitzgerald | DOWNGRADE | Overweight | Neutral |
| Mar 6, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 5, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| Feb 24, 26 | Wedbush | DOWNGRADE | Outperform | Neutral |
| Feb 24, 26 | Barclays | DOWNGRADE | Overweight | Underweight |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:80
Split dateSep 11, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-09-28
Corporate Changes & Voting Matters
8-K · 2026-09-23
Proxy Statements
DEF 14A · 2026-09-16
Corporate Changes & Voting Matters
8-K · 2026-09-11
Corporate Changes & Voting Matters
8-K · 2026-09-09
Additional Forms
D · 2026-09-04
Corporate Changes & Voting Matters
8-K · 2026-09-03
Corporate Changes & Voting Matters
8-K · 2026-08-26
Headlines
Gossamer Bio (GOSS) Stock Draws Fresh Price Target Split Before Seralutinib NDA
Simply Wall St. · 5d ago
Gossamer Bio Files New Drug Application for Seralutinib
MT Newswires · 13d ago
Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension
Business Wire · 13d ago
Gossamer Bio Appoints Greg Ciongoli to Board of Directors
Business Wire · 20d ago
Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split
Business Wire · 26d ago
Gossamer Bio Announces 1-for-80 Reverse Stock Split
Business Wire · 28d ago
Assessment of the Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, and Gossamer Bio
GlobeNewswire · 29d ago
Gossamer Bio to Present at Cantor Global Healthcare Conference
Business Wire · 33d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.